132 related articles for article (PubMed ID: 10708274)
1. Antipsychotic effects and tolerability of the sigma ligand EMD 57445 (panamesine) and its metabolites in acute schizophrenia: an open clinical trial.
Müller MJ; Gründer G; Wetzel H; Müller-Siecheneder F; Marx-Dannigkeit P; Benkert O
Psychiatry Res; 1999 Dec; 89(3):275-80. PubMed ID: 10708274
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of the sigma receptor ligand EMD 57445 (panamesine) in patients with schizophrenia: an open clinical trial.
Huber MT; Gotthardt U; Schreiber W; Krieg JC
Pharmacopsychiatry; 1999 Mar; 32(2):68-72. PubMed ID: 10333165
[TBL] [Abstract][Full Text] [Related]
3. Open clinical trial on the sigma ligand panamesine in patients with schizophrenia.
Frieboes RM; Murck H; Wiedemann K; Holsboer F; Steiger A
Psychopharmacology (Berl); 1997 Jul; 132(1):82-8. PubMed ID: 9272763
[TBL] [Abstract][Full Text] [Related]
4. Occupancy of striatal D(2)-like dopamine receptors after treatment with the sigma ligand EMD 57445, a putative atypical antipsychotic.
Gründer G; Müller MJ; Andreas J; Heydari N; Wetzel H; Schlösser R; Schlegel S; Nickel O; Eissner D; Benkert O
Psychopharmacology (Berl); 1999 Sep; 146(1):81-6. PubMed ID: 10485968
[TBL] [Abstract][Full Text] [Related]
5. Risperidone: clinical issues in treatment.
Littrell K; Schultz RE
J Psychosoc Nurs Ment Health Serv; 1994 May; 32(5):47-9. PubMed ID: 7519677
[No Abstract] [Full Text] [Related]
6. First-episode schizophrenia: the importance of early intervention and subjective tolerability.
Kasper S
J Clin Psychiatry; 1999; 60 Suppl 23():5-9. PubMed ID: 10625193
[TBL] [Abstract][Full Text] [Related]
7. Olanzapine in treatment-refractory schizophrenia: results of an open-label study. The Spanish Group for the Study of Olanzapine in Treatment-Refractory Schizophrenia.
Martín J; Gómez JC; García-Bernardo E; Cuesta M; Alvarez E; Gurpegui M
J Clin Psychiatry; 1997 Nov; 58(11):479-83. PubMed ID: 9413413
[TBL] [Abstract][Full Text] [Related]
8. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder.
Conley RR; Mahmoud R
Am J Psychiatry; 2001 May; 158(5):765-74. PubMed ID: 11329400
[TBL] [Abstract][Full Text] [Related]
9. Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia.
Conley RR; Tamminga CA; Bartko JJ; Richardson C; Peszke M; Lingle J; Hegerty J; Love R; Gounaris C; Zaremba S
Am J Psychiatry; 1998 Jul; 155(7):914-20. PubMed ID: 9659857
[TBL] [Abstract][Full Text] [Related]
10. Iloperidone for the treatment of schizophrenia: an updated clinical review.
Weiden PJ
Clin Schizophr Relat Psychoses; 2012 Apr; 6(1):34-44. PubMed ID: 22453868
[TBL] [Abstract][Full Text] [Related]
11. Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response.
Breier AF; Malhotra AK; Su TP; Pinals DA; Elman I; Adler CM; Lafargue RT; Clifton A; Pickar D
Am J Psychiatry; 1999 Feb; 156(2):294-8. PubMed ID: 9989566
[TBL] [Abstract][Full Text] [Related]
12. BMY 14802, a sigma receptor ligand for the treatment of schizophrenia.
Gewirtz GR; Gorman JM; Volavka J; Macaluso J; Gribkoff G; Taylor DP; Borison R
Neuropsychopharmacology; 1994 Feb; 10(1):37-40. PubMed ID: 7910021
[TBL] [Abstract][Full Text] [Related]
13. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group.
Zimbroff DL; Kane JM; Tamminga CA; Daniel DG; Mack RJ; Wozniak PJ; Sebree TB; Wallin BA; Kashkin KB
Am J Psychiatry; 1997 Jun; 154(6):782-91. PubMed ID: 9167505
[TBL] [Abstract][Full Text] [Related]
14. Reduced haloperidol does not interfere with the antipsychotic activity of haloperidol in the treatment of acute schizophrenia.
Ulrich S; Neuhof S; Braun V; Meyer FP
Int Clin Psychopharmacol; 1999 Jul; 14(4):219-28. PubMed ID: 10468314
[TBL] [Abstract][Full Text] [Related]
15. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group.
Small JG; Hirsch SR; Arvanitis LA; Miller BG; Link CG
Arch Gen Psychiatry; 1997 Jun; 54(6):549-57. PubMed ID: 9193196
[TBL] [Abstract][Full Text] [Related]
16. Antipsychotic medication in the treatment of schizophrenia.
Kane JM
Isr J Psychiatry Relat Sci; 1995; 32(1):30-7. PubMed ID: 7542642
[TBL] [Abstract][Full Text] [Related]
17. Antipsychotic effects of bretazenil, a partial benzodiazepine agonist in acute schizophrenia--a study group report.
Delini-Stula A; Berdah-Tordjman D
J Psychiatr Res; 1996; 30(4):239-50. PubMed ID: 8905533
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and tolerability of a new antipsychotic compound (risperidone): results of a pilot study.
Möller HJ; Pelzer E; Kissling W; Riehl T; Wernicke T
Pharmacopsychiatry; 1991 Nov; 24(6):185-9. PubMed ID: 1725925
[TBL] [Abstract][Full Text] [Related]
19. A double-blind, randomized, placebo-controlled study with JNJ-37822681, a novel, highly selective, fast dissociating D₂ receptor antagonist in the treatment of acute exacerbation of schizophrenia.
Schmidt ME; Kent JM; Daly E; Janssens L; Van Osselaer N; Hüsken G; Anghelescu IG; Van Nueten L
Eur Neuropsychopharmacol; 2012 Oct; 22(10):721-33. PubMed ID: 22464973
[TBL] [Abstract][Full Text] [Related]
20. Antipsychotic efficacy of the dopaminergic autoreceptor agonist EMD 49980 (Roxindol). Results of an open clinical study.
Klimke A; Klieser E
Pharmacopsychiatry; 1991 Jul; 24(4):107-12. PubMed ID: 1684439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
